Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Laura Evgin, Tim Kottke, Jason M. Tonne, +18

Science Translational Medicine

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, +17

Nature Communications

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy

Christopher B. Driscoll, Matthew Schuelke, Timothy Kottke, +17

Nature Communications

Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

Daniel Shu, Won Jin Ho, Luciane T. Kagohara, +36

Nature Immunology

Cancer ImmunosurveillanceHepatologyHepatocellular CarcinomaImmunologyPathology +5

The C Protein Is Recruited to Measles Virus Ribonucleocapsids by the Phosphoprotein

Christian K. Pfaller, Louis-Marie Bloyet, Ryan C. Donohue, +12

Journal of Virology

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

Timothy Kottke, Jason M. Tonne, Laura Evgin, +19

Nature Communications

CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy

Amanda L. Huff, Gabriella Longway, Jacob T. Mitchell, +17

JCI Insight

Cd8+ VaccineCancer ImmunosurveillanceCancer Vaccine EfficacyTumor GrowthImmunology +12

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy

Kevin G. Shim, Shane Zaidi, Jill Thompson, +8

Molecular Therapy

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy

Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, +12

Molecular Therapy — Oncolytics

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Laura Evgin, Amanda L. Huff, Timothy Kottke, +16

Cancer Immunology Research